HC Wainwright Has Positive Outlook for BioNTech Q2 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of BioNTech in a note issued to investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $3.78 for the quarter, up from their prior estimate of $3.72. HC Wainwright currently has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share.

Other equities analysts have also issued research reports about the company. Citigroup reiterated a "buy" rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. BMO Capital Markets lifted their price objective on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. cut their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Truist Financial restated a "buy" rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $137.86.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $0.58 during trading on Thursday, reaching $106.72. 490,569 shares of the company traded hands, compared to its average volume of 943,452. The firm's fifty day simple moving average is $102.79 and its 200 day simple moving average is $107.05. The stock has a market cap of $25.65 billion, a P/E ratio of -31.39 and a beta of 1.29. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Swedbank AB acquired a new position in shares of BioNTech during the 1st quarter worth approximately $3,415,000. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $167,000. Millennium Management LLC boosted its holdings in shares of BioNTech by 252.5% during the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company's stock worth $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of BioNTech during the 1st quarter worth approximately $80,000. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of BioNTech by 2,769.2% during the 1st quarter. Alyeska Investment Group L.P. now owns 75,000 shares of the company's stock worth $6,830,000 after purchasing an additional 72,386 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.